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Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of
malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records
were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were
recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was
4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative
incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45
tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours
were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number
of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during
the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence
allowing clinicians to inform patients in this region of their risk.
1. Introduction
Organ transplant recipients take immunosuppressive drugs
for life to prevent graft rejection. This renders them at
increased risk of many types of malignancy and they have
been found to be between four [1] and fourteen [2] times
more likely to develop cancer than age-matched controls.
They are particularly at risk of developing nonmelanoma skin
cancer (NMSC). One RCT reported that, over 20 years, 35%
of their transplant patients developed NMSC alone, when for
all other types of cancer the combined cumulative incidence
was 19% [3]. Another study found that skin cancers accounted
for 88% of cancers in the immunosuppressed patients, with
the next most frequent single malignancy being lymphoma,
at 1.4% [2]. Renal transplant recipients have been the most
extensively studied but the risk of malignancy applies to
all patients receiving long-term immunosuppression. The
cumulative dose of immunosuppression over time has been
found to be the primary factor driving the tendency towards
malignancy [2–10]. The other strong risk factor is UV light
exposure in fair-skinned transplant patients [3, 11–15]. After
20 years of follow-up, the prevalence of NMSC for these
patients has been reported to be as high as 41% in the
Netherlands [14], 61% in the UK [11], and 82% in Australia
[15].
In the South of England, there is a relatively low UV
light burden but many patients with light, high-risk skin
types. Previous regional studies have reported cumulative
incidences of 5% in Oxford (1989) [16], 19% in Oxford (2004)
[11], and 22% in London (1994) [17]. In the past, there was
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a lack of patient knowledge [18, 19], but now that more is
known about the risk of sun exposure, it might be expected
that patients would be better informed about the need for
sun protection and clinicians would be more efficient in
surveillance and detection. It is not known whether the rates
have changed in this region as, in UK, there have been fewer
than 10 published studies since 1987, with the most recent one
in 2007 [20] and the most recent London study in 1994 [17].
With the significant advance in transplantationmedicine,
it is important to have up-to-date local data to inform
practice. The aims of this study are to determine the risk of
developing skin cancer, including noninvasive tumours, for
renal transplant recipients. In addition, it will assess whether
this has changed since historical published data and provide
current data for the region to inform patients and clinicians.
2. Materials and Methods
A list of all patients receiving a renal transplant at St George’s
Hospital (SGH) between 1995 and 2008 was obtained and
demographic data were recorded onto a spreadsheet. Where
the transplant from this list was not the patient’s first one, the
date of their first transplant was obtained and used as the start
date of their immunosuppression, with the earliest case being
in 1986. The date of the most recent hospital attendance or
blood test was used to mark the last date of follow-up, unless
the patient had died, in which case the date of death was used.
The electronic pathology reports for each patient were
reviewed at each of the three hospitals where the patients
were followed up. All malignant (BCC, SCC, malignant
melanoma (MM)) skin tumours developed after the dates
of transplant were recorded. For completeness, noninvasive
tumours (Bowen’s disease (SCC in situ) and actinic keratosis)
were also recorded. Keratoacanthoma behaves like SCC in
immunosuppressed patients and for the purposes of this
study, these were classified as well-differentiated SCC. The
date of the pathology report, site of the tumour, subtype of
BCC, grade of SCC, and Breslow thickness for MM were
recorded.
The scope of this study was limited to skin tumours,
and nonskin malignancies were not recorded or analysed.
The three cohorts followed up at three sites were analysed
separately and appeared similar; therefore, the combined data
are analysed and those results are shown. Statistical testing
was conducted with Quickcalcs (Graphpad) and XLSTAT
(Addinsoft) and Fisher’s exact test was used to test signif-
icance. This project was reviewed and approved by (SGH),
Audit Department, and assigned a project number (DB314).
3. Results
Demographic data are shown in Table 1. There were 769
patients who received a kidney transplant at SGH, London,
between 1995 and 2008. 20 (2.6%) transferred out of the area,
15 (2.0%)were removed from the sample for having less than 3
months follow-up time, and 25 (3.3%) were lost to follow-up.
The remaining 709 patients were all followed up in South East
England with 346 at SGH, 192 at St Helier Hospital, London,
Table 1: Patient demographic data and results at a glance.The results
show themean length of follow-up from time of transplant to time of
the most recent electronic entry to the patient’s record, the interval
between tumours in those that developed at least two, and the mean
number of tumours developed.
Demographics and results at a glance
Patients, 𝑛 709
Males, 𝑛 (%) 458 (65)
Females, 𝑛 (%) 251 (35)
Mean length follow-up, yrs (SD) 7.2 (3.9)
Total follow-up in person-years 4926
Mean age at transplant, yrs (SD) 46 (13.0)
Patients with skin types I–III (white), 𝑛 (%) 567 (80)
Patients with malignant skin tumour, 𝑛 (%) 53 (7.5)
Mean time to 1st tumour, yrs (SD) 5.8 (3.3)
Mean tumours per patient (SD) 4 (8.5)
Mean tumour interval, yrs (SD) 1 (1.4)
and 171 at the Royal Sussex County Hospital, Brighton. On
average, the medical records for these patients covered 84.3%
of the maximum achievable follow-up time.
53 of 709 patients (7.5%) had at least one malignant skin
tumour (Table 1). The rate of skin cancer was 45 per 1000
person-years at risk. 39 of 458 males (8.5%) and 14 of 251
females (5.6%) had at least one malignant tumour (OR 1.6,
𝑃 = 0.18) (Figure 1). 49 (6.9%) had an NMSC. 36 (5.1%) had
at least one BCC and 21 (3.0%) had an SCC, with 8 patients
(11.3%) having both tumour types. 6 patients (0.8%) had an
MM, with 2 (0.3%) having both MM and NMSC.
Additionally, 21 (3.0%) only developed noninvasive
tumours (Bowen’s disease (BD) and actinic keratosis (AK))
which may progress to invasive SCC. For those noninvasive
tumours, there were 31 patients with 88 tumours. Of these, 21
never developed an SCC and these patients had a total of 23
of the noninvasive skin tumours described above.
Only one (1.9%) of the patients who developed a skin
tumour following transplantation was nonwhite (Fitzpatrick
skin types IV–VI) (Figure 2), compared with the ethnic mix
of the local transplant population being 64% white, 14%
African or Caribbean, 13% South Asian, 6% East Asian, and
3% fromother ethnic groups.The rate of skin cancer for white
transplant patients was 57 per 1000 person-years at risk.
Of the 247 patients with 3-month to 5-year follow-up,
10 (4.0%) developed a total of 22 malignant skin tumours
(12 BCCs, 10 SCCs); of the 281 with 5–10-year follow-up, 21
(7.5%) developed a total of 49 tumours (36 BCCs, 9 SCCs,
4 MMs); of the 181 patients with over 10-year follow-up
22 (12.2%) developed 150 tumours (56 BCCs, 92 SCCs, 2
MMs).This last group included a patient who had his original
transplant in 1986. After 25 years of immunosuppression, he
developed 55 SCCs, 21 noninvasive tumours (BD or AK),
and 2 BCCs between 1996 and 2011. Another notable patient
had 8 pretransplant BCCs over 6 years and developed 22
posttransplant BCCs and none of the other tumour types over
his 9 years of posttransplant follow-up.
Of the 221 malignant tumours that were found, 104
(47.1%) were BCC, 111 (50.2%) were SCC, and 6 (2.7%) were
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Figure 1:The absolute numbers and percentages of male and female
kidney transplant recipients in our study population who received
a renal transplant between 1995 and 2008 and had developed a
malignant skin tumour at the time of data collection.
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Figure 2: Kaplan Meier survival curve shows two groups—patients
with Fitzpatrick skin types I–III (light-skinned—L) with worse
times to first malignant tumour and patients with Fitzpatrick
types IV–VI (dark skinned—D) where only one malignant tumour
occurred.
MM. In addition, there were 88 noninvasive tumours, of
which 26 were BD and 62 were AK (Figure 3).
Of the BCCs, 76 were on the head and neck, 12 on the
trunk, 9 on the upper limb, and 7 on the lower limb. Of the
SCCs, 37 were on the head and neck, 3 on the trunk, 71 on
the upper limb, and none on the lower limb (Figure 4). Of
the noninvasive tumours, 33 were on the head and neck, 8 on
the trunk, 38 on the upper limb, and 8 on the lower limb and
in one case the location was not documented. Of the MMs, 1
was on the head and neck, 4 on the trunk, none on the upper
limb, and 1 on the lower limb.
For BCC subtype, 63 (61%) were nodular; 16 (15%)
were superficial type; 14 (13%) were infiltrative; 1 (1%) was
basosquamous; and for 10 (10%) the subtype was not docu-
mented.
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Figure 3: Frequency of skin tumour types among renal transplant
recipients in the study population.
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Figure 4: Anatomical distribution of NMSC tumours shows pre-
dominance in sun-exposed sites.
For SCC grade, 53 (48%) were well differentiated; 29
(26%) were moderately differentiated; 1 (1%) was poorly dif-
ferentiated and for 28 SCCs (25%) the grade was not docu-
mented.
For the thickness of the 6 MMs, 3 were <1mm; 1 was 1-
2mm, and 2 were 2–4mm.
4. Discussion
Cumulative incidences of skin tumours following renal trans-
plantation reported in the literature have varied according to
length of follow-up of the sample and the inclusion criteria
for tumours in the analysis.The 7.5% cumulative incidence of
NMSC (10.5% if noninvasive tumours are added) observed in
this study is comparable to those observed in other studies of
similar design and follow-up period [11, 14, 16, 17].
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Whilst only 4% of patients at <5 years follow-up devel-
oped a tumour, our department begins annual screening
immediately after transplant as recommended byThe Ameri-
can Society of Transplantation [21]. Our observed cumulative
incidences of 7.5% and 12.2% for those with >5- and >10-
year follow-up, respectively, contrast with 23% (>5 years) and
44% (>9 years) in sunlight-rich Australia [22].This illustrates
the importance of sun avoidance and annual screening is
an opportunity to identify high-risk patients and impart
education.
The BCC : SCC ratio was equalized at 1 : 1, compared to
7 : 1 in the normal population [23, 24], showing the particular
risk of SCC for transplant patients. This is thought to be
related to HPV which is known to be an important aetio-
logical factor in SCC but not for BCC or MM (whereas sun
exposure is an aetiological factor for all three). The precise
mechanism is not clear and is the subject of some debate.
There is some evidence that HPV infection, which is often
transient, damages cellular DNA in a “hit and run” fashion,
not by genomic integration as it does for cervical cancer [25,
26]. However, HPV genes such as E6 and E7 have been found
to persist in the DNA of host SCCs, suggesting that at least
some element of the pathogenesis is not entirely transient
[27]. Ultimately HPV is thought to interfere with tumour
suppressor genes such as p53 which would normally initiate
apoptosis or repair genetic damage caused, for instance, by
UV light [8, 17]. Importantly for immunosuppressed patients,
they may be more susceptible to acquiring HPV infection
in the first place, with 90% of transplant patients infected at
a given time [28]. Furthermore, HPV types which are not
known to be oncogenic (e.g., HPV 1/2) may become so in
transplant patients and oncogenic strains (e.g., HPV 16/18)
which are normally confined to the mucosa may manifest in
the skin of transplant patients [29].
This study did not explore the role of different immuno-
suppressive drugs as these have been compared exten-
sively elsewhere with no advantage between the commonly
used regimes [3, 30]. The majority of our renal transplant
recipients were on a calcineurin inhibitor (tacrolimus or
cyclosporine) with either prednisolone or an antiproliferative
agent (mycophenolate mofetil or azathioprine). There is
emerging evidence to suggest that the newerm-Tor inhibitors
(sirolimus/everolimus) may confer an advantage in reducing
de novomalignancies in comparison to calcineurin inhibitors
[4–6], though this finding applies to organ transplant recip-
ients with a low and early SCC burden only. Longer-term
evidence for the newer agents will emerge in the future, but
current evidence suggests that the cumulative immunosup-
pressive load remains the most important risk factor [3].
Many of the limitations of this study are those inherent
to the retrospective study design. In particular, it is not
certain that all tumours were accounted for, as there may
have been tumours which did not present to our service
and therefore would not have been on the hospital records
(e.g., if a patient presented to their GP and a sample was
not taken). However, this scenario can be expected to be
rare because of the education given to our GPs around the
increased risks associated with skin malignancy in patients
on immunosuppression.
Because this is a case series and the cohort is not
compared to matched controls, the obtained figures are open
to fluctuations depending on the nature of this cohort and
baseline population rates are not accounted for. Confounding
factors within the cohort such as the proportion with fair
skin, age at transplant, length of follow-up, and underlying
genetic susceptibilities may have influenced the results. The
only randomised control trial (RCT) on this subject was
recently published in Australia and found an overall NMSC
cumulative incidence of 35% at 20-year median follow-up
[3]. This is lower than previous retrospective studies which
have been reported, even in low-sunlight areas such asOxford
where 61% was reported [10]. The cumulative incidence
observed in our study approximates to the RCT’s predicted
incidence for low-risk patients, which was 1.9% at 5 years,
4.2% at 10 years, and 9.3% thereafter [3]. This would be
expected in a region of lower sun exposure such as UK and
supports the validity of our results.
Our findings being slightly lower than some previous UK
studies may show the impact of patient education, as the 20-
year follow-uppatients in previous retrospective cohortswere
transplanted before the era of increased awareness of the risk
of sun exposure (e.g., the highly successful Australian “Slip!
Slap! Slop!” public health campaign started in 1981) which
is not the case in the RCT cohort recruited between 1983
and 1986. It also shows the importance of individual patient
susceptibility, as 77% of patients in the RCT had olive or
darker, less susceptible skin types (indeed the authors predict
a 99% rate for fair-skinned high-risk patients). Transplant
patients should be educated to understand their particular
danger from sun exposure and they should avoid direct
sunlight and use sun protection factor 50. Skin color is
important, as highlighted by the low risk in patients in our
cohort with skin types IV–VI (all but one of the malignant
tumours in our cohort were seen in patients with skin types
I–III).The variability in risk between different patients should
be formally assessed by clinicians, with high-risk patients
identified for increased surveillance.
5. Conclusion
This study provides recent data for London and South East
England. Despite changes in transplantation practice during
the time since the last datawere published in this region, these
findings are similar to those of previous studies. This study
adds to the evidence allowing clinicians in temperate regions
to inform patients of their risk of developing skin tumours
after renal transplantation.
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